The Invisible
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View The Invisible as PDF for free.
More details
- Words: 542
- Pages: 19
Seeing
the invisible
Today’s presentation • Charles Laycock, CEO • Objectives • Markets & marketing • Ophthalmology • Defence & other markets • Outlook
Seeing
the invisible
Conventional Image
2006 objectives Completed
•
Completed milestones 1 - 4 of DSTO CTD contract
9
•
Constructed prototype camera test bed for CTD contract
9
•
Obtained first order from GE Healthcare
9
•
Completed ophthalmology proof of concept for auto-refractor
9
•
Simplified capital structure and converted options
9
2007 objectives Completed
•
Letter of agreement with international ophthalmology manufacturer
•
Finalise test work on auto-refractor prototype and handover to manufacturer – February 2007
•
License agreement with ophthalmology equipment manufacturer – March 2007
•
CTD defence contract milestones 5 – 8, including the first military field demonstration in March 2007
9
Commercialisation • Geography - 75% west coast USA • Reference site e.g. GE Healthcare • Connections & networks • Technical people to technical people • Resources - develop or market
Target markets High value markets in both biological and material areas: • Medical Ophthalmology, pathology and academic research
• Bio-pharmaceutical Automated cell analysis, assay and targeting
• Nanotechnology Electron microscopy, X-ray imaging, semi-conductor quality assurance
• Defence CTD contract
Market focus • Platform technology with many applications • One area of focus - niche high return • Looking for best risk reward ratio • Ophthalmology • Existing technical knowledge • Known growth market
Ophthalmology • Growth market - especially with aging populations • Wave front sensing is the “must have” technology • QPI will provide ophthalmologists with better measurement & software tool for early detection of eye diseases and general eye health • Current target 4 to 5 products
Ophthalmology THEM
Shack Hartman
US
Auto-refractor •
Measures quality (power) of eye’s vision for eyeware.
•
QPI gives megapixel resolution • Measure more subtle aberrations in eyes • Better diagnosis & better prescriptions
•
Infra-red LED light so no OHS issues
Progress
Defence and homeland security • Changing military requirements brings need for new technologies to: • negate camouflage • allow for passive, undetectable surveillance and target ranging • DSTO CTD contract - three years & up to $2.7 mill. • Developing QPI to enable imaging over greater distances • International interest from other key military organisations • Large markets but long development lead times
The concept Seeing
the invisible
Conventional Image
Iatia Processed Shape Image
Progress to date • Completed and received payment milestones 1 to 4 • Prototype camera test bed constructed • First military field trial scheduled for March 2007
Picture of prototype
Outlook • Further direct marketing will generate additional opportunities • 2007 & 2008 New product development & license agreements in all 4 markets • 2007 November launch of auto-refractor • 2008 Projected first year profit, strong growth thereafter
Why Iatia will be a success •
Proven patented technology
•
Successful products in the market
•
Extensive application pipeline
•
Applications that target large as well as niche markets
•
Agreements & alliances with high quality organisations
•
Research and development spending
•
Experienced management
“We find this product quite remarkable” Dr. David J Brenner, Professor of Radiation Oncology & Public Health, Columbia University Medical Centre, New York, USA
Live unstained human fibroblast cells
Seeing
the invisible
the invisible
Today’s presentation • Charles Laycock, CEO • Objectives • Markets & marketing • Ophthalmology • Defence & other markets • Outlook
Seeing
the invisible
Conventional Image
2006 objectives Completed
•
Completed milestones 1 - 4 of DSTO CTD contract
9
•
Constructed prototype camera test bed for CTD contract
9
•
Obtained first order from GE Healthcare
9
•
Completed ophthalmology proof of concept for auto-refractor
9
•
Simplified capital structure and converted options
9
2007 objectives Completed
•
Letter of agreement with international ophthalmology manufacturer
•
Finalise test work on auto-refractor prototype and handover to manufacturer – February 2007
•
License agreement with ophthalmology equipment manufacturer – March 2007
•
CTD defence contract milestones 5 – 8, including the first military field demonstration in March 2007
9
Commercialisation • Geography - 75% west coast USA • Reference site e.g. GE Healthcare • Connections & networks • Technical people to technical people • Resources - develop or market
Target markets High value markets in both biological and material areas: • Medical Ophthalmology, pathology and academic research
• Bio-pharmaceutical Automated cell analysis, assay and targeting
• Nanotechnology Electron microscopy, X-ray imaging, semi-conductor quality assurance
• Defence CTD contract
Market focus • Platform technology with many applications • One area of focus - niche high return • Looking for best risk reward ratio • Ophthalmology • Existing technical knowledge • Known growth market
Ophthalmology • Growth market - especially with aging populations • Wave front sensing is the “must have” technology • QPI will provide ophthalmologists with better measurement & software tool for early detection of eye diseases and general eye health • Current target 4 to 5 products
Ophthalmology THEM
Shack Hartman
US
Auto-refractor •
Measures quality (power) of eye’s vision for eyeware.
•
QPI gives megapixel resolution • Measure more subtle aberrations in eyes • Better diagnosis & better prescriptions
•
Infra-red LED light so no OHS issues
Progress
Defence and homeland security • Changing military requirements brings need for new technologies to: • negate camouflage • allow for passive, undetectable surveillance and target ranging • DSTO CTD contract - three years & up to $2.7 mill. • Developing QPI to enable imaging over greater distances • International interest from other key military organisations • Large markets but long development lead times
The concept Seeing
the invisible
Conventional Image
Iatia Processed Shape Image
Progress to date • Completed and received payment milestones 1 to 4 • Prototype camera test bed constructed • First military field trial scheduled for March 2007
Picture of prototype
Outlook • Further direct marketing will generate additional opportunities • 2007 & 2008 New product development & license agreements in all 4 markets • 2007 November launch of auto-refractor • 2008 Projected first year profit, strong growth thereafter
Why Iatia will be a success •
Proven patented technology
•
Successful products in the market
•
Extensive application pipeline
•
Applications that target large as well as niche markets
•
Agreements & alliances with high quality organisations
•
Research and development spending
•
Experienced management
“We find this product quite remarkable” Dr. David J Brenner, Professor of Radiation Oncology & Public Health, Columbia University Medical Centre, New York, USA
Live unstained human fibroblast cells
Seeing
the invisible
Related Documents
The Invisible
June 2020 25
The Invisible Mentor
June 2020 13
The Invisible Man
April 2020 16
Mapping The Invisible Landscape
December 2019 25
The Invisible Web
April 2020 9